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A B S T R A C T
Heparin proteoglycans (HEP-PGs) carry standard heparin-mediated anticoagulant properties as well as novel antiplatelet functions, a combination that may be
significant for targeting multiple pathways in a single therapy. Recent work developing semisynthetic HEP-PG mimetics has shown promising results also in vivo,
however flow conditions in vitro that replicate in vivo hemodynamics have not been reported. In this work, we present several assays (platelet calcium mobilization,
aggregometry, microfluidic tests at venous and arterial hemodynamics) to characterize specific mechanistic effects of dual antiplatelet and anticoagulant (APAC)
constructs as mimetics of HEP-PGs. Three APACs with different conjugation levels of heparin chains (CL10, CL18, HICL) were shown to decrease platelet deposition
to collagen surfaces in PPACK-treated whole blood at venous shear rate (200 s−1). FXIIa-inhibited whole blood (CTI: corn trypsin inhibitor, 40 μg/mL) perfused over
collagen/tissue factor showed reduced both platelet and fibrin deposition when treated with APACs. IC50 values for platelet and fibrin inhibition were calculated for
each molecule at venous shear rate. Increasing the shear rate to arterial flows (1000 s−1) and using APAC as the sole anticoagulant, resulted in a more potent
antiplatelet effect of APAC, suggesting an added effect on von Willebrand Factor (vWF) function. Additionally, APAC caused an inhibition of calcium mobilization
specific to thrombin and collagen stimulation and a dose-dependent reduction in collagen-mediated platelet aggregation. Understanding the sensitivity of APAC
activity to shear rate, platelet signaling and procoagulant pathways is important for applications in which APAC administration may have beneficial therapeutic
effects.
1. Introduction
Antithrombotic drugs are typically classified into one of three major
categories: antiplatelet, anticoagulant, or fibrinolytic agents [1, 2].
Common antiplatelet therapeutics include aspirin and clopidogrel
which both inhibit secondary platelet agonist generation (thromboxane
A2 and ADP, respectively) [1–3], as well as inhibitors of the integrin
ɑIIb/β3 [4]. Anticoagulants are responsible for preventing thrombin
generation and fibrin polymerization. Warfarin and various heparins
have been used as an oral and parental anticoagulant for several dec-
ades, but recent advances have focused on specifically targeting coa-
gulation factors, such as thrombin and factor Xa [1]. Finally, fi-
brinolytic or thrombolytic drugs (most notably tPA: tissue plasminogen
activator) promote the generation of plasmin, an enzyme that cleaves
fibrin [5].
With increasingly complex cardiovascular disease states comes a
need for the administration of multiple antithrombotics with different
mechanisms of action. While certain classes of drugs have the potential
to function synergistically, there is an associated increased bleeding risk
as the number of drugs increases [6, 7]. Therefore, identifying a method
for combining the antithrombotic functions of antiplatelet and antic-
oagulant agents into a single therapy can have a potentially great im-
pact on the field, as uncertainty regarding optimal use remains [7].
Heparin (usually referred to as unfractionated heparin; UFH) is yet
another common clinically-used antithrombotic agent which carries
anticoagulant behavior through its binding and activation of antith-
rombin. Antithrombin then works to deactivate circulating thrombin
and factor Xa to hinder the coagulation process [8]. Heparin can bind
directly to thrombin (Kd=100 nM) resulting in anticoagulant behavior
[9]. Heparin is derived from mast cells which line the vascular walls
usually in the same general location as tissue factor (TF). Upon tissue
injury, mast cells are activated and release heparin proteoglycans (HEP-
PGs) which are much higher in molecular weight than UFH [10, 11].
These structures have been shown to exhibit both anticoagulant
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features, as does heparin typically [12], as well as specific antiplatelet
properties, most notably involving the platelet-collagen interaction and
subsequent aggregation and fibrin polymerization [10]. The un-
conventional ability for a heparin-based entity to impact collagen-de-
pendent platelet activation could be attributed to the fact that type I
collagen has binding sites for heparin, in addition to the heparin
binding site to von Willebrand Factor (vWF) bridging platelets with
collagen, relevant under arterial shear rates [13]. The concept of de-
signing synthetic HEP-PG mimetics, structured with a protein core and
conjugated with UFH, has been demonstrated [10, 11, 14, 15].
Despite various results comparing the ability of HEP-PGs and UFH
to inhibit collagen-mediated platelet aggregation and serotonin release
under flow conditions [10], previous work with dual anticoagulant and
antiplatelet (APAC) conjugates has been focused primarily on in vitro
platelet aggregometry studies and in vivo vascular models [11, 15]. The
importance of understanding the functionality of APACs, as is the case
with any novel therapy, in more pathophysiologic scenarios in vitro is
crucial. Thus, the focus of this work was to compare the results obtained
from various in vitro experimental techniques to gain a broader un-
derstanding for the potential therapeutic effect of synthetic HEP-PG
mimetics with varying heparin conjugation levels (CL10, CL18, HICL).
2. Materials and methods
2.1. Reagents
Reagents were obtained as follows: Anti-human CD61 (BD
Biosciences, San Jose, CA), Alexa Fluor® 647 conjugated human fi-
brinogen (Life Technologies, Waltham, MA), corn trypsin inhibitor and
D-Phe-Pro-Arg-chloromethylketone (CTI and PPACK, respectively;
Haematologic Technologies, Essex Junction, VT), Sigmacote® silico-
nizing reagent (Sigma, St. Louis, MO), Dade® Innovin® PT reagent
(Siemens, Malvern, PA), collagen Type I Chrono-Par™ aggregation re-
agent (Chrono-log, Havertown, PA). Whole blood was drawn via veni-
puncture from healthy donors following University of Pennsylvania
Institutional Review Board approval into a syringe loaded with 100 μM
PPACK (to inhibit thrombin activity altogether for the study of platelet
deposition on collagen only) or 40 μg/mL CTI (to inhibit contact
pathway and measure platelet and fibrin deposition). Prior to each
blood draw, donors self-reported to be free of any medications for
7 days and alcohol use for 48 h. Additionally, female donors self-re-
ported to not using oral contraceptives.
Apixaban (SelleckChem, Houston, TX), HEPES (Fisher Scientific,
Hampton, NH), Fluo-4 NW calcium dye and probenecid (Invitrogen,
Carlsbad, CA), ADP (Sigma-Aldrich, St. Louis, MO), U46619 (Tocris
Bioscience, Bristol, UK), convulxin (Cayman Chemical, Ann Arbor, MI),
type I fibrillar collagen (Chrono-log, Havertown, PA), thrombin
(Haematologic Technologies Inc., Essex Junction, VT), and SFLLRN and
AYPGKF amide (Bachem, Torrance, CA), Protein A Sepharose CL-4B
(GE Healthcare, US), vWF (Wilfactin®, 100 IU/mL, LFB
Fig. 1. Platelet deposition is dose-dependently reduced by APAC in the absence of thrombin under 200 s−1 over collagen in microfluidic assay. Vehicle (1% BSA) or
APAC (CL18, 30 μg/mL) was added to PPACK-treated whole blood and perfused over collagen under venous shear rate. (A) images of platelet deposition, (B)
dynamics of platelet deposition and (C) dose-response curve and IC50 (± standard deviation [SD]).
Table 1
IC50 values calculated at venous shear rate for PPACK and CTI-treated whole
blood. IC50 values were calculated for each APAC species (CL10, CL18, and
HICL) under two different anticoagulated whole blood conditions (PPACK and
CTI). Since PPACK inhibits all thrombin activity, APAC-driven inhibition was
only observed on platelet deposition. CTI-treated whole blood enabled the
calculation of IC50 for both platelet deposition and fibrin polymerization.
IC50 (μg/ml), 200 s−1
PPACK High CTI
Platelet Platelet Fibrin
APAC CL10 Not determined 25 0.6
APAC CL18 27 71 5.4
APAC HICL 57 90 0.5
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Biomedicaments, Les Ulis, FR), rabbit polyclonal anti-vWF (DAKO,
Glostrup, DK), enhanced chemiluminescent (ECL) detection reagents
(GE Healthcare, US), goat anti-rabbit HRP, (Jackson Immunoresearch,
Westgrove, PA, US), streptavidin-ATTO647 (Immune Biosolutions,
Sherbrooke, QE, CA) were stored and used according to each manu-
facturer's instructions. Three different APAC molecules were synthe-
sized (Aplagon, Helsinki, Finland) as previously described [11, 15]. In
brief, dual antiplatelet and anticoagulant (APAC) conjugate comprises
of protein core, where UFH chains are bound by covalent di-sulfide
bridges provided by a cross-linker molecule to reach various conjuga-
tion levels (CL) of heparin.
2.2. Microfluidic assays
Microfluidic experiments were run as previously described [16].
Glass slides were treated with Sigmacote®. A volume of 5 μL of collagen
was perfused through a patterning channel device (250 μm wide and
60 μm high) to create a single strip of fibrillar collagen. Lipidated TF
was then sorbed to the collagen surface by introduction of 5 μL of Dade
Innovin PT reagent (20 μM stock concentration). The Dade Innovin PT
reagent was incubated with the collagen for 30min without flow and
then blocked and rinsed with 20 μL of bovine serum albumin (1% BSA
in Hepes-buffered saline). An 8-channel microfluidic device was va-
cuum-mounted perpendicularly to collagen/TF surfaces forming 8
parallel-spaced prothrombotic patches (250×250 μm). APAC (CL10
7.12mg/mL; CL18 11.94mg/mL or HICL 6.71mg/mL in phosphate-
buffered saline, PBS, 10mM Na2HPO4, 0.137M NaCl, pH 7.5) was di-
luted in 1% BSA for appropriate concentrations for the analysis. Vehicle
(1% BSA) or APAC-treated blood was perfused across the 8 channels at
an initial wall shear rate controlled by a syringe pump (Harvard PHD
2000; Harvard Apparatus, Holliston, MA). Each thrombus was formed
under constant flow rate (constant Q). Platelet and/or fibrin deposition
were monitored simultaneously by epifluorescence microscopy (IX81;
Olympus America Inc., Center Valley, PA). Images were captured with a
charged coupled device camera (Hamamatsu, Bridgewater, NJ) and
were analyzed with ImageJ software (National Institutes of Health). To
avoid side-wall effects, fluorescence values were taken only from the
central 75% of the channel. The background-corrected fluorescence
values were fitted by use of a log (inhibitor concentration) vs. response
routine in GraphPad Prism 5.00 (GraphPad Software) to calculate the
half-maximal inhibitory concentration (IC50).
Fig. 2. APAC inhibits platelet deposition dose-dependently with simultaneous anticoagulant efficacy under 200 s−1 over collagen/TF in microfluidic assay. Vehicle
(1% BSA) or APAC (HICL, 30 μg/mL) was added to CTI-treated whole blood and perfused over collagen/TF under venous shear rate. (A) images of platelet and fibrin
deposition, (B) dynamics of platelet deposition, (C) dose-response curve and IC50 for platelet deposition, (D) dynamics of fibrin polymerization, (E) dose-response
curve and IC50 for fibrin polymerization (± standard deviation [SD]).
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2.3. Immunoprecipitation to detect vWF and APAC binding
Rabbit polyclonal anti-vWF (1:5000) was first attached to Protein A
Sepharose CL-4B and used to capture vWF (50 μg of Wilfactin®, final)
and vWF-specific APAC-biotin (CL10, 8 μg in PBS, pH 7.5). Between
each step Protein A Sepharose was spun down, and washed thrice with
PBS. Samples were run under reduced conditions (β-mercaptoethanol)
on SDS-PAGE (6%) and Western-blotted on polyvinylidene difluoride
membrane. VWF was detected with goat anti-rabbit HRP and APAC-
biotin with Streptavidin-ATTO647 (1:1000).
2.4. Platelet calcium assays
Measurements of platelet calcium mobilization were conducted in
384-well plate assay format, as described previously [17]. Briefly, fresh
whole blood treated with 250 nM apixaban (a Factor Xa inhibitor used
to eliminate endogenous thrombin generation) was centrifuged (120 g,
10 min) to isolate platelet-rich plasma (PRP). The PRP was incubated
with a vial of Fluo-4 NW calcium dye prepared by reconstitution with
sterile 20mM HEPES-buffered saline (HBS, pH 7.4) and 77mg/mL
probenecid to prevent dye leakage for 30min. After incubation, two
separate 384-well plates were assembled. One plate contained dye-
loaded PRP (30 μL/well) and the other plate contained platelet agonists
at previously determined EC50 concentrations [17, 18], as well as serial
dilutions of three different APAC molecules of varying heparin con-
jugation levels (CL10, CL18, HICL). The agonist-containing plate was
prepared using a JANUS liquid handling system (PerkinElmer, Inc.,
Waltham, MA) such that all 144 combinations of the six platelet ago-
nists and eight APAC concentrations (0, 1.56, 3.12, 6.25, 12.5, 25, 50,
100 μg/mL) were prepared in a time-efficient manner with replicates.
The two plates were loaded into a FlexStation 3 microplate reader
(Molecular Devices, Inc., Sunnyvale, CA) and agonists (20 μL/well)
were dispensed column-wise into PRP. The dynamic fluorescence in-
tensity F(t) was read and normalized by the pre-dispense baseline (Fo)
for 4.5min with readings every 2.5 s (Ex: 485 nm; Em: 525 nm). The
final PRP concentration after agonist addition was 12% by volume and
previously no evidence of autocrine signaling has been reported in
these dilute conditions [17]. Testing of type I fibrillar collagen (20 μg/
mL) in the platelet calcium assay was performed as previously de-
scribed [19], in which manual pipetting and reading using a Fluoroskan
Ascent plate reader was required due to variable delivery of collagen by
the FlexStation automated pipetting system.
2.5. Platelet aggregometry
Platelet aggregation studies were performed using a Chrono-log
Fig. 3. Dose-response curves for each APAC species at venous shear rate. Inhibition on platelet deposition and fibrin formation under two anticoagulated whole blood
conditions (PPACK and CTI) at venous shear rate (200 s−1) of CL10 (A), (B), (C). CL18 (D), (E), (F). HICL (G), (H), (I) (± standard deviation [SD]).
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Model 700 Whole Blood/Optical Lumi-Aggregation System. Whole
blood was drawn via venipuncture into a syringe loaded with 250 nM
apixaban and 4% (w/v) sodium citrate (Sigma-Aldrich) under the same
IRB approval as above. Citrated whole blood is commonly used to
chelate calcium ions and prevent platelet activation, but here we use
citrate in conjunction with apixaban to further ensure minimal en-
dogenous thrombin generation. Type I fibrillar collagen (1 μL) was
added to PRP after 10min incubation of APAC (or buffer as control) and
aggregation was measured for 4min post-dispense.
3. Results
3.1. APAC has antiplatelet activity in the absence of thrombin under venous
shear rate upon collagen
The 8-channel device, developed by Maloney et al. [20], has been
used to investigate platelet function and coagulation in whole blood
under flow. Briefly, eight inlets of treated or untreated blood were
perfused over collagen (with or without TF) while platelet and fibrin
deposition can be monitored. The first aim was to determinate the
antiplatelet effectiveness alone, without the influence of thrombin and
fibrin. PPACK, a direct thrombin inhibitor, was added as an antic-
oagulant and blood was perfused over collagen at a shear rate of
200 s−1. CL18 (30 μg/mL) inhibited platelet deposition (Fig. 1A) at
both early times (100 s) of attachment to collagen and at later times
(180 to 420 s) where secondary deposition was occurring, via ADP/
thromboxane enhancement [21, 22]. CL18 caused a dose-dependent
inhibition (IC50=27 μg/mL, based on endpoint fluorescence at 400 s)
(Fig. 1B-C). In similar tests with PPACK-treated whole blood, HICL also
reduced platelet deposition (IC50=57 μg/mL), while CL10 had un-
clear effect of inhibition on platelet deposition (IC50, not determined)
(Table 1, Fig. 3A).
3.2. APAC shows both antiplatelet and anticoagulant activity under venous
shear rate upon collagen/TF
High level of CTI (40 μg/mL), a FXIIa inhibitor, was used to avoid
clot formation in the reservoir, which allowed the combined study of
platelet deposition in the presence of thrombin/fibrin production.
Blood was perfused (at the shear rate of 200 s−1) over collagen/TF strip
to initiate extrinsic pathway. HICL at 30 μg/mL reduced both platelet
and fibrin deposition at venous flow condition with fibrin production
strongly antagonized (Fig. 2A). HICL produced a dose-dependent in-
hibition of both platelet (IC50=90 μg/mL) and fibrin deposition
(IC50=0.5 μg/mL) (Fig. 2B-E, Fig. 3H-I). Similar tests were run for
CL10 (Platelet IC50=25 μg/mL; Fibrin IC50= 0.6 μg/mL) and for
CL18 (Platelet IC50=71 μg/mL; Fibrin IC50= 5.4 μg/mL) (Table 1,
Fig. 3B-C, Fig. 3E-F). For the 3 APAC constructs tested at venous
thrombotic conditions, each construct was considerably more potent
(> 13 to 180-fold) against thrombin generation/fibrin deposition in
comparison to inhibition of platelet deposition.
3.3. APAC in whole blood is more potent as an antiplatelet agent under
arterial than venous flow
Microfluidic methods allow the rapid testing of non-anticoagulated,
Fig. 4. APAC is more efficient in antiplatelet activity under arterial shear rate compared to venous shear rate. APAC (CL10, 10 μg/mL) was added to non-antic-
oagulated, freshly-drawn whole blood and perfused over collagen/TF under (A) venous shear rate and (B) arterial shear rate. APAC has stronger effect on inhibition
of platelet deposition. (C), (D) dynamics of platelet deposition and (E), (F) dynamics of fibrin generation (± standard deviation [SD]).
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Fig. 5. VWF captures APAC under static conditions, (A) detection of vWF and (B) of APAC. Direct interaction of vWF and APAC was studied with im-
munoprecipitation. vWF was bound to rabbit polyclonal anti-vWF coated beads and used to capture APAC. In (A), vWF (Wilfactin®) was detected with goat anti-
rabbit HRP, and in (B), APAC (CL10)-biotin conjugate was detected with streptavidin-ATTO647. Samples for both (A) and (B) were as follows: 1. and 2. vWF captured
APAC (in duplicate), 3. vWF bound to rabbit polyclonal anti-vWF coated beads, 4. rabbit polyclonal anti-vWF coated beads, and 5. APAC-biotin (8 μg). SDS-PAGE (6-
%) was run under reducing conditions, resulting in APAC splitting into its constituents, a core protein and UFH. SB=Protein A Sepharose CL-4B beads. vWF=von
Willebrand factor.
Fig. 6. Thrombin- and collagen-dependent calcium mo-
bilization is specifically reduced in the presence of APAC.
Previously determined EC50 concentrations [17, 18] of
several platelet agonists were added to dilute apixaban-
treated PRP to stimulate platelet activation. A control
condition (absence of APAC) was used as the 100% cal-
cium mobilization baseline to which the effect of three
APACs (12.5 μg/mL) was compared. Antiplatelet effects
were seen by reduced activation levels in cases where
thrombin and fibrillar collagen were used as the stimulus.
However, all other platelet agonists were not significantly
hindered by APAC. Final agonist concentrations:
thrombin, 20 nM; collagen, 20 μg/mL; CVX, 2 nM; ADP,
1 μM; U46619, 1 μM; SFLLRN, 10 μM; AYPGKF, 300 μM.
(n=3 donors, * p < 0.05, mean ± SD). PRP=platelet-
rich plasma.
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freshly-drawn whole blood, enabling the determination of clotting in
the presence of FXII [16]. Blood samples need to be carefully handled
and minimally perturbed. The concentration of APAC was chosen to be
10 μg/mL to match the IC50 order in the previous experiment. Whole
blood treated with CL10 (10 μg/mL) was immediately perfused over a
collagen/TF surface at either venous (200 s−1) or arterial (1000 s−1)
perfusion. At this low concentration under venous perfusion, there was
little antagonism of platelet deposition, but strong antagonism of fibrin
deposition (as shown in Table 1). In contrast, under the arterial per-
fusion condition, CL10 displayed considerable potency against both
platelet and fibrin deposition (Fig. 4), suggesting that CL10 may an-
tagonize vWF pathways required for platelet deposition at arterial flow
conditions. As expected, there was considerably less fibrin generated
under control conditions (no CL10) at arterial flow compared to venous
flow (Fig. 4E-F). Finally, APAC and vWF interaction was confirmed by
immunoprecipitation, where APAC (CL10, biotinylated) was captured
by vWF under static conditions (Fig. 5A and B).
3.4. APAC specifically inhibits calcium mobilization due to thrombin and
fibrillar collagen but has no effect on other platelet agonists
Intracellular calcium mobilization of dilute apixaban-treated PRP in
response to several platelet agonists was measured in the presence and
absence of three different APAC molecules. Platelet agonists included
thrombin (20 nM), convulxin (a potent platelet glycoprotein (GPVI)
activator derived from snake venom; 2 nM), ADP (1 μM), U46619 (a
stable thromboxane A2 analog; 1 μM), fibrillar collagen (20 μg/mL),
and two PAR-specific ligands SFLLRN (PAR-1 agonist; 10 μM) and
AYPGKF (PAR-4 agonist; 300 μM). All APAC concentrations
(1.56–100 μg/mL) reduced the platelet calcium response to thrombin
and collagen at least 50% compared with the negative control condi-
tion. Representative results for 12.5 μg/mL of APAC are shown in
Supplementary Fig. S1.
For each condition, the area under the curve of the resultant calcium
fluorescence trace was calculated and converted to a percentage of the
control response (Fig. 6). The effect of heparin conjugation level was
also identified to impact the extent of inhibition. Incubation of PRP
with CL10 resulted in a 76% decrease in thrombin-induced platelet
calcium signal and 51% reduction in the collagen response. CL18
showed the highest attenuation of calcium mobilization, yielding an
83% and 95% reduction in response to thrombin and collagen, re-
spectively. However, increasing the conjugation level above 18 (HICL)
still exhibited a statistically significant inhibition, but slightly less than
that seen with CL18 and closer to that of CL10. For each of the other
five agonists tested, virtually no inhibitory effect was observed, as is
evident by ~100% calcium mobilization (Fig. 6). Heparin inhibition of
thrombin-mediated platelet calcium mobilization was fully consistent
with accelerated thrombin complexation with antithrombin via the
heparin functionality of the constructs, while maintaining PAR-1/4
functionality, as evidenced by the unchanged responses to SFLLRN and
AYPGKF stimuli. In addition to this anticoagulant feature, previous
work has shown the APAC conjugates to also display antiplatelet effects
[11], however the effects on intracellular calcium mobilization have
not been reported. The antiplatelet effects appear to be specific to
collagen and thrombin, since all other platelet signaling pathways and
receptor agonists (CVX, ADP, U46619, SFLLRN, and AYPGKF for GPVI,
P2Y1/12, TP, PAR1, and PAR4, respectively) were active in the pre-
sence of APAC. While collagen can bind heparin, convulxin has no
known heparin-binding domain, thus likely explaining the striking
difference in APAC activity against collagen stimulation of the platelets
that remain fully responsive to the GPVI activator, convulxin.
3.5. APAC reduces collagen-induced platelet aggregation
In a similar test as previously reported [11], aggregometry was used
to investigate the antiplatelet features of the heparin proteoglycan
mimetic APAC. Each individual APAC (100 or 200 μg/mL final con-
centration) or buffer was added to PRP, and type I fibrillar collagen
(2 μg/mL) was used as the stimulus to measure platelet aggregation in
citrated PRP with apixaban addition. The negative control condition
(buffer treatment) produced 70% aggregation over the course of the
experiment (4 min). For each APAC species (CL10, CL18, and HICL),
aggregation was impaired in a dose-dependent manner (Fig. 7A-C). In
all cases, the maximal aggregation was lowered, the lag time prior to
aggregation was prolonged, and the slope and area under the curve
were reduced. The intermediate-chain conjugated species (CL18) was
again observed to have the most significant effect, as platelet ag-
gregation was completely abolished at high concentrations (200 μg/
mL) (Fig. 7B). Other platelet agonists were screened in aggregometry
and the same observations were made in that APAC conjugates only
affect thrombin- and collagen-mediated platelet aggregation
Fig. 7. Platelet aggregation in PRP is inhibited by APAC. A dose-dependent
reduction in collagen-mediated aggregation of apixaban/sodium citrate-treated
PRP was observed for each of three APACs (A. CL10; B. CL18; C. HICL). A high
dose of CL18 was shown to have the greatest effect as aggregation was almost
completely abolished, consistent with the calcium mobilization findings re-
ported in the previous section. PRP=platelet-rich plasma.
J. Chen et al. Thrombosis Research 169 (2018) 143–151
149
(Supplemental Fig. S2), confirming the calcium mobilization results.
4. Discussion
Concern of bleeding risks associated with combinations of two or
more blood modulating drugs have sparked interest in developing
cardiovascular therapies with dual antiplatelet and anticoagulant
(APAC) activity. Using naturally-produced HEP-PGs as a framework for
synthetic alternatives, protein functionalized with conjugated UFH
chains offers a promising route [11, 15]. With our 8-channel device, we
demonstrated APAC antiplatelet activity with PPACK-treated blood
perfused upon collagen. Secondly, we analyzed the ability of APAC to
interfere with the thrombus growth when CTI-treated blood was per-
fused upon a collagen/TF surface. We also provide evidence that APACs
can directly interact with collagen to reduce platelet deposition under
flow and to decrease collagen-induced calcium mobilization. Ad-
ditionally, the increased inhibitory activity against platelets under ar-
terial flow conditions suggests that APAC when studied in the absence
of any other anticoagulant may also reduce vWF binding to collagen or
modulate the VWF-GPIbα interaction. APAC interaction with vWF was
supported by the immunoprecipitation studies where vWF captured
APAC (Fig. 5). A schematic summarizing the major results from
Figs. 1–3 is shown in Fig. 8.
To investigate the observed antiplatelet effects of APAC more spe-
cifically, we utilized intracellular calcium mobilization as a metric to
test the influence of APAC on various platelet signaling pathways. The
activation of several platelet receptors leads to distinct signaling cas-
cades that converge on mobilization of calcium ions, so we can infer the
level of agonist-induced activation through this reading. A screen of
seven common platelet agonists in the presence and absence of three
APAC conjugates revealed inhibitory action only towards thrombin and
fibrillar collagen (Fig. 5, Supplementary Fig. S1). All other agonists
(ADP, U46619, convulxin, SFLLRN, and AYPGKF) were sufficiently
active with respect to the control buffer condition. Collagen-induced
aggregation was also impaired by each APAC molecule (Fig. 7). These
results suggest that APAC has specific antiplatelet targets without being
a universal inhibitor of platelet activation, leaving the other activation
routes intact.
Other than its traditional anticoagulant mechanism, heparin has
been implicated to exhibit other antithrombotic effects such as in-
hibiting endoperoxide metabolites that lead to thromboxane A2 pro-
duction, suggesting aspirin-like functions [23]. Also, collagen has pre-
viously been reported to have unique heparin-binding sites separate
from those involved in heparin-triggered thrombin inactivation [13, 24,
25]. Though the functional significance of heparin-collagen binding is
still unclear, it may explain the observed inhibitory phenomenon of
heparin proteoglycans and synthetic APAC conjugates on collagen-in-
duced platelet aggregation, especially under blood flow.
Collagen activates platelets primarily through GPVI, a uniquely non-
G protein-coupled receptor. GPVI belongs to a class of proteins known
as immunoreceptor tyrosine-based activation motifs (ITAM) [26]. The
converse to ITAM receptors are immunoreceptor tyrosine-based in-
hibition motifs (ITIM), which inhibit ITAM signaling in order to sup-
press platelet activation, a pathway that functions along with the
prostacyclin-activated IP receptor [27, 28]. Upon first consideration, it
would appear, that the APAC conjugates would qualify as ITIM-acti-
vating molecules, but the calcium mobilization results showing full
GPVI activity via convulxin disproves this hypothesis and points more
towards the collagen-heparin interaction. Though certain explanations
may be incorrect, and collagen and thrombin appear to be the sole
targets, more work should be performed to further refine the specific
antiplatelet and platelet anticoagulant mechanisms of APAC.
Currently available treatment by antithrombotics is available only
systemically. In our previous, publications we have shown that during
local application at the vascular injury site, either in vivo (arterial
model of crush injury in baboon) or on the collagen-coated surface ex
vivo (collagen coated chamber - shunt model in baboons) APAC inhibits
platelet thrombosis and reduces platelet accumulation under arterial
shear forces [11]. In addition, we have previous data to show by PET
scan that APAC ([64Cu]-APAC) binds at the injury site with extended
retention time in comparison with UFH ([64Cu]-UFH) [15]. Our recent
data (K. Barreiro et al., submitted) also show targeting and localization
of APAC at the injury site in porcine models of balloon denuded iliac
and carotid arteries and at the arteriovenous fistula of femoral artery
and vein. Based on the results of our current manuscript showing re-
duced platelet deposition on the highly thrombogenic collagen/tissue
factor surface and the inhibition of collagen- and thrombin-induced
platelet activation and aggregation support the suggestion to combine
Fig. 8. Schematic of APAC functionality as both
antiplatelet and anticoagulant agent. APAC has
anticoagulant effect by accelerating the in-
activation of thrombin and factor Xa through an
antithrombin-dependent mechanism. Its anti-
platelet activity results from inhibition on pla-
telet-collagen interactions. APAC strongly in-
hibited platelet deposition under arterial shear
rate by attenuating GPIbα-vWF mediated acti-
vation. vWF= von Willebrand factor.
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antiplatelet and anticoagulant action in a single antithrombotic, locally
acting modality. These actions do not exclude the simultaneous sys-
temic use of e.g. acetylsalicylic acid. Importantly, polyvalent APAC
constructs may offer PK/PD advantages relative equivalent free drug.
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